Contrarian picks that promise big profits

Alec Cutler of Orbis Global Balanced Fund finds three stocks ripe with opportunity.

Each week, a professional investor tells us where he'd put his money. This week: Alec Cutler of Orbis GlobalBalanced Fund finds three stocks ripe with opportunity.

Buying cheap stocks and holding onto them for a very long time is a winning investment strategy. While this may sound obvious, investors aren't stupid and cheap stocks are often cheap for a reason.This is the challenge for contrarian investors. In times of extreme negativity, a company might appear uninvestable at any price. Take a closer look, however,and there may be an opportunity investors have missed.

Subscribe to MoneyWeek

Become a smarter, better informed investor with MoneyWeek.

A transformed oil major

The result? BP is now growing production with lower spending, and the barrels from new projects are more profitable than the barrels they replace, resulting in much higher free cash flow. Yet the stock is still priced at a near-6% dividend yield and 14 times consensus earnings for 2019, reflecting ongoing pessimism about the industry.

Take a long-term view of AbbVie

While this blockbuster drug drives considerable earnings and cash flow for AbbVie, the market is concerned about how AbbVie will grow once it loses US patent protection on Humira in 2023. Instead of maximising sales of Humira through to 2023, AbbVie will intentionally cannibalise Humira revenue with its two new drugs, which are proving to be more effective than Humira.

Advertisement - Article continues below

We believe that cannibalising in return for longer patent protection is the right strategy for the long term, but realise that this is likely to make for a bumpy ride in the short to medium term. We are happy to wait. At less than ten times our 2019 earnings estimate and a yield of 5.3%, AbbVie currently has one of the lowest valuations and highest yields in the sector, despite industry-leading earnings growth and one of the most active and promising late-stage drug pipelines.

Investors ignore Bayer's benefits

In addition, the seed business has profited from decades of investment and research into product development, which have made it very difficult for rivals to gain a foothold. Bayer also has a high-quality pharmaceutical business; at eight times consensus earnings for 2019 for the company overall, the market is clearly ignoring that too.

Indeed, we believe the market is overestimating the costs of the Roundup affair. The current price implies the settlement would be more than £700,000 per plaintiff, which is well above the pay-outs for similar suits in the past, and in our opinion highly unlikely.



Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 Dec 2019
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Dec 2019

Most Popular


Three things matter for the UK housing market now – and “location” isn’t one of them

The UK housing market is frozen. And when it does eventually thaw out, the traditional factors that drive prices will no longer apply. The day of reck…
1 Apr 2020

What does the coronavirus crisis mean for UK house prices?

With the whole country in lockdown, the UK property market is closed for business. John Stepek looks at what that means for UK house prices, housebuil…
27 Mar 2020

Oil shoots higher – have we seen the bottom for the big oil companies?

Just a few days ago everyone was worried about negative oil prices. Now, the market has turned upwards. John Stepek explains what’s behind the rise an…
3 Apr 2020
UK Economy

How the coronavirus pandemic is killing cash

Covid-19 is making a huge difference to the way we live, work and do business. One of its less obvious effects, says Merryn Somerset Webb, is to accel…
31 Mar 2020